





Cat No: **BRC491 – Breast cancer tissue array**

Lot#	Cores	Size	Cut	Format	QA/QC	Pantomics, Inc.	
BRC49101	49	1.7mm	4um	6X9	H&E, IHC anti-Cytokeratin		

Recommended applications: For Research use only. RNA or protein breast cancer/non-tumor tissue profiling using IHC or ISH; Antibody characterization.

Description: Breast cancer tissue array, 49 cores including 49 cases of breast cancers. All the tissues were from surgical resection. They were fixed in 10% neutral buffered formalin for 24 hours and processed using identical SOPs. Sections were picked onto Superfrost Plus or APES coated Superfrost slides. They all have a guaranteed six months' shelf-life at 4C from the date of shipment. Each slide has >95% tissue core retention.

Position	Age	Sex	Site	Histology	Grade	Stage	
A1	28	F	Breast	Ductal carcinoma	I	TisN0M0	ER+, HER2++
A2	63	F	Breast	Invasive ductal carcinoma	II~III	T2N2M0	ER-, HER2-
A3	43	F	Breast	Invasive ductal carcinoma	II~III	T2N1M0	ER-, HER2-
A4	74	F	Breast	Invasive ductal carcinoma	II~III	T2N0M0	ER+++, HER2-
A5	60	F	Breast	Invasive ductal carcinoma	II~III	T2N2M0	ER+++, HER2-
A6	49	F	Breast	Tumor tissue has run out			
B1	41	F	Breast	Ductal carcinoma	I	TisN0M0	ER++, HER2++
B2	43	F	Breast	Invasive ductal carcinoma	II	T2N0M0	ER-, HER2+++
B3	44	F	Breast	Invasive ductal carcinoma	II	T2N0M0	ER++~++++, HER2++
B4	50	F	Breast	Invasive ductal carcinoma	I~II	T2N0M0	ER-, HER2+++
B5	48	F	Breast	Invasive ductal carcinoma	II~III	T4N3M1	ER+~+++ , HER2+++
B6	54	F	Breast	Invasive ductal carcinoma	III	T2N0M0	ER-, HER2-
C1	43	F	Breast	Invasive ductal carcinoma	II	T2N0M0	ER-, HER2+++
C2	48	F	Breast	Invasive ductal carcinoma	III	T2N0M0	ER+, HER2+
C3	40	F	Breast	Invasive ductal carcinoma	III	T2N0M0	ER-, HER2++
C4	50	F	Breast	Invasive ductal carcinoma	II	T2N0M0	ER-, HER2+
C5	35	F	Breast	Invasive ductal carcinoma	II	T2N0M0	ER++~++++, HER2+
C6	92	F	Breast	Invasive ductal carcinoma	III	T2N0M0	ER-, HER2+++
D1	41	F	Breast	Invasive ductal carcinoma	III	T2N0M0	ER++, HER2+++
D2	47	F	Breast	Invasive ductal carcinoma	III	T2N0M0	ER+++, HER2+
D3	28	F	Breast	Invasive ductal carcinoma	I~II	T2N0M0	ER+++, HER2-
D4	42	F	Breast	Invasive ductal carcinoma	III	T2N0M0	ER-, HER2+++
D5	50	F	Breast	Invasive ductal carcinoma	II~III	T4N3MX	ER-, HER2+++
D6	68	F	Breast	Invasive ductal carcinoma	II~III	T3N1M0	ER+++, HER2-
E1	64	F	Breast	Invasive ductal carcinoma	II~III	T2N0M0	ER-, HER2+++
E2	62	F	Breast	Invasive ductal carcinoma	II~III	T2N0M0	ER-, HER2+++
E3	50	F	Breast	Invasive ductal carcinoma	II	T1N0M0	ER-, HER2+++
E4	50	F	Breast	Invasive ductal carcinoma	II~III	T4N3M1	ER++~++++, HER2++
E5	65	F	Breast	Invasive ductal carcinoma	II	T2N0M0	ER-, HER2+
E6	50	F	Breast	Invasive ductal carcinoma	I	T3N0M0	ER-, HER2+++



Advancing Biomedical Science Through Tissue Arrays

F1	47	F	Breast	Invasive ductal carcinoma	II~III	T3N0M0	ER+, HER2+~+++
F2	53	F	Breast	Invasive ductal carcinoma	III	T2N1M0	ER-~+, HER2+++
F3	51	F	Breast	Invasive ductal carcinoma	II~III	T4N2M1	ER+++ , HER2+
F4	44	F	Breast	Invasive lobular carcinoma	II~III	T1N0M0	ER++ , HER2+
F5	45	F	Breast	Tumor tissue has run out			
F6	51	F	Breast	Invasive ductal carcinoma	II	T2N1M0	ER-, HER2+++
G1	33	F	Breast	Invasive ductal carcinoma	III	T2N0M0	ER-, HER2+++
G2	42	F	Breast	Mucinous carcinoma	II	T2N0M0	ER++~++++, HER2++~++++
G3	48	F	Breast	Invasive ductal carcinoma	II~III	T2N0M0	ER+++ , HER2+
G4	61	F	Breast	Invasive ductal carcinoma	II~III	T2N0M0	ER-, HER2+++
G5	37	F	Breast	Invasive ductal carcinoma	III	T2N0M0	ER-, HER2-
G6	44	F	Breast	Invasive ductal carcinoma	I	T2N0M0	ER++ , HER2+++
H1	55	F	Breast	Invasive ductal carcinoma	III	T2N0M0	ER-, HER2-~+
H2	31	F	Breast	Invasive ductal carcinoma	II~III	T2N1M0	ER+++ , HER2+++
H3	46	F	Breast	Invasive lobular carcinoma	III	T3N1M0	ER++ , HER2+
H4	36	F	Breast	Adeno/squamous cell carcinoma	II	T2N0M0	ER+++ , HER2+~+++
H5	57	F	Breast	Invasive ductal carcinoma	II~III	T2N0M0	ER+++ , HER2+
H6	52	F	Breast	Invasive ductal carcinoma	II~III	T3N3M0	ER-, HER2-
I1	46	F	Breast	Invasive ductal carcinoma	II	T2N0M0	ER+++ , HER2+~+++

Notes: Bake at 60C for 30 minutes before use.

Certified by: Langxing Pan, M.D.

TNM Classification: Breast carcinoma

T- Primary tumor

- TX - Primary tumor cannot be assessed
- TO - No evidence of primary tumor
- Tis - Carcinoma in situ, intraductal carcinoma or lobular carcinoma in situ, or Paget's disease of the nipple with no tumor
- T1 - Tumor 2 cm or less in greatest dimension
- T2 - Tumor more than 2 cm but not more than 5 cm in greatest dimension
- T3 - Tumor more than 5 cm in greatest dimension
- T4 - Tumor of any size with direct extension to chest wall or skin

N - Regional lymph nodes

- NX - Regional lymph nodes cannot be assessed
- NO - No regional lymph node metastasis
- N1 - Metastasis to movable ipsilateral lymph node(s)
- N2 - Metastasis to ipsilateral lymph nodes(s) fixed to one another or to other structure
- N3 - Metastasis to ipsilateral internal mammary lymph node(s)

M - Distant metastasis



Pantomics, Inc

Phone: 415-863-2380

Support: info@pantomics.com

Web: www.pantomics.com

Advancing Biomedical Science Through Tissue Arrays

MX - Distant metastasis cannot be assessed

MO - No distant metastasis

M1 - Distant metastasis

TNM classification of malignant tumours, Fifth Edition (1997)